Lu AA21004 shows highly significant results in clinical phase II trial

The clinical trial was a multicenter, double-blind, placebo-controlled trial including 426 patients with major depression. Lu AA21004 showed highly significant improvements on the primary efficacy endpoints with both 5 and 10 mg compared to placebo and had an attractive safety profile.

 

"We are pleased that the encouraging results from this proof of concept study confirm our experimental expectations of Lu AA21004 as a potent and well tolerated new drug for the treatment of major depression," says Anders Gersel Pedersen, Head of Development at Lundbeck and continues: "Lu AA21004 is the most advanced project within the new bis-aryl-sulphanyl amine class of compounds for the treatment of mood disorders and anxiety, and we look forward to further exploiting the potential of these novel projects."     

 

Lu AA21004 is jointly being developed by H. Lundbeck A/S and Takeda Pharmaceutical Company Limited. Following analysis of the phase II data, Lundbeck and Takeda will plan the next steps in the development of Lu AA21004.

 

The content of this release will have no influence on the Lundbeck Group's financial result for 2007.

 

Lundbeck contacts

 

Investors:	Media:
Jacob Tolstrup	Caroline Broge
Director, Investor Relations	Media Relations Manager
+45 36 43 30 79	+45 36 43 26 38
+1 201 350 0187

 

________________________

 

 

Stock Exchange Release No 296 - 2 October 2007

 

About Lundbeck

H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approximately 5,300 globally. For further information, please visit www.lundbeck.com